Nuvectis Pharma (NVCT) Common Equity (2021 - 2026)
Nuvectis Pharma (NVCT) posted Common Equity of $14.2 million for Q1 2026, down 22.77% sequentially from $18.4 million in Q4 2025, and down 32.14% YoY from $21.0 million in Q1 2025.
Nuvectis Pharma (NVCT) Common Equity (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Common Equity for 6 years, with the latest figure at $14.2 million in Q1 2026.
- Quarterly Common Equity fell 32.14% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (down 32.14% YoY) and the FY2025 annual result came in at $18.4 million, up 89.57% from the prior year.
- Common Equity fell to $14.2 million in Q1 2026 per NVCT's latest filing, from $18.4 million in the prior quarter.
- Over five years, Common Equity peaked at $24.0 million in Q3 2025 and troughed at $9.7 million in Q4 2024.
- A 5-year average of $15.5 million and a median of $14.2 million in 2026 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity jumped 361.36% in 2022, then tumbled 38.38% in 2024.
- Over 5 years, Common Equity stood at $14.2 million in 2022, then decreased by 14.19% to $12.2 million in 2023, then slipped by 20.39% to $9.7 million in 2024, then surged by 89.57% to $18.4 million in 2025, then decreased by 22.77% to $14.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $14.2 million, $18.4 million, and $24.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 9.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.08 Mn |
| Mar 31, 2026 | 14.22 Mn |
| Dec 31, 2025 | 18.41 Mn |
| Sep 30, 2025 | 24.01 Mn |
| Jun 30, 2025 | 16.87 Mn |
| Mar 31, 2025 | 20.95 Mn |
| Dec 31, 2024 | 9.71 Mn |
| Sep 30, 2024 | 10.99 Mn |
| Jun 30, 2024 | 12.53 Mn |
| Mar 31, 2024 | 14.02 Mn |
| Dec 31, 2023 | 12.20 Mn |
| Sep 30, 2023 | 16.69 Mn |
| Jun 30, 2023 | 20.33 Mn |
| Mar 31, 2023 | 12.27 Mn |
| Dec 31, 2022 | 14.22 Mn |
| Sep 30, 2022 | 20.37 Mn |
| Jun 30, 2022 | 11.50 Mn |
| Mar 31, 2022 | 14.56 Mn |
| Dec 31, 2021 | -11.01 Mn |
| Sep 30, 2021 | -8.93 Mn |